Millipore Sigma Vibrant Logo

AB7356 Anti-von Willebrand Factor Antibody

View Products on
100 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
Limited Quantities Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers


      Contact Customer Service


      Replacement Information

      Key Specifications Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, RELISA, IH(P), WBRbPurifiedPolyclonal Antibody
      Catalogue NumberAB7356
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-von Willebrand Factor Antibody
      Alternate Names
      • Factor VIII Related Antigen
      Background Informationvon Willebrand factor (UniProt: P04275; also known as vWF) is encoded by the VWF (also known as F8VWF) gene (Gene ID:7450) in human. vWF is a multimeric plasma glycoprotein that is synthesized by endothelial cells and plays an important in the maintenance of hemostasis. It is synthesized with a signal peptide (aa 1-22), which is subsequently cleaved off in the mature form. vWF is known to promote adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. vWF also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Mutations in VWF gene are linked to von Willebrand diseases 1-3 that are common hemorrhagic disorders caused by impaired platelet aggregation. Two isoforms of vWF have been described that are produced by alternative splicing.
      Product Information
      PresentationPurified rabbit immunoglobulin in buffer containing 0.02 M PBS pH 7.6, 0.25 M NaCl with 0.1% sodium azide.
      Quality LevelMQ100
      ApplicationAnti-von Willebrand Factor, Cat. No. AB7356, is a rabbit polyclonal antibody that detects von Willebrand Factor and has been tested for use in ELISA, Immunohistochemistry, and Western Blotting.
      Key Applications
      • ELISA
      • Immunohistochemistry (Paraffin)
      • Western Blotting
      Application NotesImmunohistochemistry Analysis: A representative lot detected von Willebrand Factor in Immunohistochemistry applications.

      ELISA Analysis: A representative lot detected von Willebrand Factor in ELISA applications.

      Immunohistochemistry Analysis: A 1:250-1,000 dilution from a representative lot detected von Willebrand Factor in human cerebral cortex, mouse hippocampus, rat cerebellum and human tonsil tissue sections.
      Biological Information
      ImmunogenHuman von Willebrand Factor purified from plasma.
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      SpecificityAB7356 is specific for vWF by ELISA against the human protein and by immunohistochemistry. The antibody is reactive in paraffin embedded tissues on human, rat, and mouse. Other species not tested. Antibody has not been evaluated by western blot analysis for reactivity to vWF.
      Species Reactivity
      • Human
      • Mouse
      • Rat
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThe glycoprotein encoded by this gene functions as both an antihemophilic factor carrier and a platelet-vessel wall mediator in the blood coagulation system. It is crucial to the hemostasis process. Mutations in this gene or deficiencies in this protein result in von Willebrand's disease. An unprocessed pseudogene has been found on chromosome 22.
      Gene Symbol
      • VWF
      • F8VWF
      • F8
      • vWF
      • VWD
      Purification MethodProtein A Purfied
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P04275 # Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
      SIZE: 2813 amino acids; 309299 Da
      SUBUNIT: Multimeric. Interacts with F8.
      SUBCELLULAR LOCATION: Secreted. Note=Localized to storage granules.
      DOMAIN: SwissProt: P04275 The von Willebrand antigen 2 is required for multimerization of VWF and for its targeting to storage granules.
      PTM: All cysteine residues are involved in intrachain or interchain disulfide bonds.
      DISEASE: SwissProt: P04275 # Defects in VWF are associated with various forms of von Willebrand disease (VWD) [MIM:193400, 277480]. VWD is characterized by frequent bleeding (gingival, minor skin quantitative lacerations, menorrhagia, etc.). Type I VWD is associated with a deficiency of VWF; type II by normal to decreased plasma level of VWF; type III by a virtual absence of VWF. There are subtypes (A to H) of type II VWD; for example: type IIA is characterized by the absence of VWF high molecular weight multimers in plasma.
      SIMILARITY: Contains 1 CTCK (C-terminal cystine knot-like) domain. & Contains 4 TIL (trypsin inhibitory-like) domains. & Contains 3 VWFA domains. & Contains 3 VWFC domains. & Contains 4 VWFD domains.
      Molecular Weight~250 kDa observed; 309.26 kDa calculated. Uncharacterized bands may be observed in some lysate(s).
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceImmunohistochemistry(paraffin):
      Representative images from a previous lot.
      Rabbit anti-vWF (AB7356) staining of Human Cerebral Cortex. Tissue pretreated with Citrate Buffer, ph 6.0, anti-vWF at 20 μg/mL, IHC-Select Detection with HRP-DAB.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at 2-8ºC from date of receipt.
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information



      AB7356 IH(P) Summary

      Anti-von Willebrand Factor Antibody SDS


      Safety Data Sheet (SDS) 

      Anti-von Willebrand Factor Antibody Certificates of Analysis

      TitleLot Number
      Anti-von Willebrand Factor - 2142168 2142168
      Anti-von Willebrand Factor - 2428720 2428720
      Anti-von Willebrand Factor - 2455686 2455686
      Anti-von Willebrand Factor - 1987046 1987046
      Anti-von Willebrand Factor - 2064704 2064704
      Anti-von Willebrand Factor - 2279535 2279535
      Anti-von Willebrand Factor - 2489066 2489066
      Anti-von Willebrand Factor - 3239865 3239865
      Anti-von Willebrand Factor - 3455235 3455235
      Anti-von Willebrand Factor - 3691360 3691360


      Reference overviewApplicationSpeciesPub Med ID
      Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage.
      Yougbaré, I; Lang, S; Yang, H; Chen, P; Zhao, X; Tai, WS; Zdravic, D; Vadasz, B; Li, C; Piran, S; Marshall, A; Zhu, G; Tiller, H; Killie, MK; Boyd, S; Leong-Poi, H; Wen, XY; Skogen, B; Adamson, SL; Freedman, J; Ni, H
      The Journal of clinical investigation  125  1545-56  2015

      Show Abstract
      25774504 25774504
      Multi-omic integrated networks connect DNA methylation and miRNA with skeletal muscle plasticity to chronic exercise in Type 2 diabetic obesity.
      Rowlands, DS; Page, RA; Sukala, WR; Giri, M; Ghimbovschi, SD; Hayat, I; Cheema, BS; Lys, I; Leikis, M; Sheard, PW; Wakefield, SJ; Breier, B; Hathout, Y; Brown, K; Marathi, R; Orkunoglu-Suer, FE; Devaney, JM; Leiken, B; Many, G; Krebs, J; Hopkins, WG; Hoffman, EP
      Physiological genomics  46  747-65  2014

      Show Abstract
      25138607 25138607
      Antagonizing the αv β3 integrin inhibits angiogenesis and impairs woven but not lamellar bone formation induced by mechanical loading.
      Tomlinson, RE; Schmieder, AH; Quirk, JD; Lanza, GM; Silva, MJ
      Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research  29  1970-80  2014

      Show Abstract
      24644077 24644077
      Multiphasic construct studied in an ectopic osteochondral defect model.
      Jeon, JE; Vaquette, C; Theodoropoulos, C; Klein, TJ; Hutmacher, DW
      Journal of the Royal Society, Interface / the Royal Society  11  20140184  2014

      Show Abstract
      24694896 24694896
      A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone.
      Thibaudeau, L; Taubenberger, AV; Holzapfel, BM; Quent, VM; Fuehrmann, T; Hesami, P; Brown, TD; Dalton, PD; Power, CA; Hollier, BG; Hutmacher, DW
      Disease models & mechanisms  7  299-309  2014

      Show Abstract
      24713276 24713276
      Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.
      Noda, S; Asano, Y; Nishimura, S; Taniguchi, T; Fujiu, K; Manabe, I; Nakamura, K; Yamashita, T; Saigusa, R; Akamata, K; Takahashi, T; Ichimura, Y; Toyama, T; Tsuruta, D; Trojanowska, M; Nagai, R; Sato, S
      Nature communications  5  5797  2014

      Show Abstract
      Immunohistochemistry25504335 25504335
      Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response.
      Baik, J; Stringer, KA; Mane, G; Rosania, GR
      Antimicrobial agents and chemotherapy  57  1218-30  2013

      Show Abstract
      23263006 23263006
      Autologous minced muscle grafts: a tissue engineering therapy for the volumetric loss of skeletal muscle.
      Corona, BT; Garg, K; Ward, CL; McDaniel, JS; Walters, TJ; Rathbone, CR
      American journal of physiology. Cell physiology  305  C761-75  2013

      Show Abstract
      23885064 23885064
      Endothelial Progenitors Exist within the Kidney and Lung Mesenchyme.
      Sims-Lucas, S; Schaefer, C; Bushnell, D; Ho, J; Logar, A; Prochownik, E; Gittes, G; Bates, CM
      PloS one  8  e65993  2013

      Show Abstract
      23823180 23823180
      Spatiotemporal control of vascular endothelial growth factor expression using a heat-shock-activated, rapamycin-dependent gene switch.
      Martín-Saavedra, FM; Wilson, CG; Voellmy, R; Vilaboa, N; Franceschi, RT
      Human gene therapy methods  24  160-70  2013

      Show Abstract
      23527589 23527589

      Related Products & Applications

      Related Products

      Catalog Number Description  
      05-861 Anti-vWF (von Willebrand Factor) Antibody, clone GMA-022 Show Pricing & Availability

      Product Families


      Life Science Research > Antibodies and Assays > Primary Antibodies